Allogeneic hematopoietic SCT in children with ALL: Current concepts of ongoing prospective SCT trials

Bone Marrow Transplantation

Volumn 41, Issue SUPPL. 2, 2008, Pages

  Schrauder, A ^a   von Stackelberg, A ^b   Schrappe, M ^a   Cornish, J ^c   Peters, Christina ^d  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^d ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE COURSE; DONOR SELECTION; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; LEUKEMIA REMISSION; MORTALITY; MYELOABLATIVE CONDITIONING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; STEM CELL MOBILIZATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 45749121232     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.58     Document Type: Article

References (25)

1. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze O et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000; 14: 2205-2222.
2. von Stackelberg A, Seeger K, Henze G, Eckert C. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004; 18: 1727-1728; author reply 8-9.
3. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study. Lancet 2005; 366: 635-642.
4. Borgmann A, von Stackelberg A, Hartmann R, Ebell W, Klingebiel T, Peters C et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis. Blood 2003: 101: 3835-3839.
5. Peters C, Schrauder A, Schrappe M, von Stackelberg A, Stary J, Yaniv I et al. Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: The BFM/IBFM/EBMT concepts. Bone Marrow Transplant 2005; 35 (Suppl 1): S9-S11.
6. Niethammer D, Klingebiel T, Ebell W, Henze G. Paolucci P. Riehm H. Which children do benefit from bone marrow transplant? The EBMT Paediatric Diseases Working Party. Bone Marrow Transplant 1996; 18 (Suppl 2): 43-46.
7. Oakhill A, Pamphilon DH, Potter MN, Steward CG. Goodman S. Green A et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574-578.
8. Leung WH, Turner V, Richardson SL, Benaim E, Hale G. Horwitz EM et al Effect of HLA class I or class II incompatibility in pediatric marrow transplantation from unrelated and related donors. Hum Immunol 2001: 62: 399-407.
9. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial. Blood 2000; 95: 1572-1579.
10. Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A. Messina C et al Chronic graft-versus-host disease in children: Incidence, risk factors, and impact on outcome. Blood 2002; 100: 1192-1200.
11. Rocha V. Cornish J. Sievers EL. Filipovich A. Locatelli F. Peters C et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-2971.
12. Bordigoni P, Esperou H, Souillet G, Pico J, Michel G, Lacour B et al Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: A Societe Francaise de Greffe de Moelle study. Br J Haematol 1998; 102: 656-665.
13. Dopfer R. Henze G. Bender-Gotze C. Ebell W. Ehninger G. Friedrich W et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: Results of the German Cooperative Study. Blood 1991; 78: 2780-2784.
14. Spitzer TR, Peters C, Ortlieb M, Tefft MC, Torrisi J, Cahill R et al Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. Int J Radiat Oncol Biol Phys 1994; 29: 39-44.
15. Carpenter PA, Marshall GM, Giri N, Vowels MR, Russell SJ. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Bone Marrow Transplant 1996; 18: 489-494.
16. Klingebiel T, Henze G. Ebell W. Reiter A, Zintl F, Bender GC et al Bone marrow transplantation in children for ALL in 2nd and 3rd remission with preparation by TBI and etoposide. Blood 1998: 92 352b.
17. Pui CH. Gaynon PS. Boyea JM, Chessells JM, Baruchel A, Kamps W et al Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915.
18. Locatelli F. Nollke P. Zecca M. Korthof E. Lanino E. Peters C et al Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EBMT trial. Blood 2005; 105: 410-419.
19. Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E et al. Haematopoietic stem cell transplantation trends in children over the last three decades: A survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007; 30: 89-99.
20. Peters C. Minkov M. Gadner H. Klingebiel T. Niethammer D. Proposal for standard recommendations for prophylaxis of graft-versus-host disease in children. European Group for Blood and Marrow Transplantation (EBMT) Working Party Paediatric Diseases and the International Study Committee of the BFM family-subcommittee Bone Marrow Transplantation (IBFM-STG). Bone Marrow Transplant 1998; 21 (Suppl 2): S57-S60.
21. Peters C. Another step forward towards improved outcome after HLA-haploidentical stem cell transplantation. Leukemia 2004; 18 1769-1771.
22. Lang P, Schumm M, Greil J, Bader P, Klingebiel T, Muller I et al. A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: Preliminary results of a pilot study. Klin Padiatr 2005; 217: 334-338.
23. Matthes-Martin S, Aberle SW, Peters C, Holter W, Popow-Kraupp T, Potschger U et al. CMV-viraemia during allogenic bone marrow transplantation in paediatric patients: Association with survival and graft-versus-host disease. Bone Marrow Transplant 1998; 21 (Suppl 2): S53-S56.
24. Hayes C, Lush RJ, Cornish JM, Foot AM, Henderson J, Jenkins I et al The outcome of children requiring admission to an intensive care unit following bone marrow transplantation. Br J Haematol 1998; 102: 666-670.
25. Koehler M, St George K, Ehrlich GD, Mirro Jr J, Neudorf SM, Rinaldo C. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy. J Pediatr Hematol Oncol 1997; 19: 43-47.